In this article, we will list the 5 Best Performing Healthcare Stocks So Far in 2026. Please visit 10 Best Performing Healthcare Stocks So Far in 2026 if you would like to see the extended list and the methodology behind it.
A healthcare professional in full protective gear performing a medical procedure.
5. Oruka Therapeutics, Inc. (NASDAQ:ORKA)
YTD Share Price Gain: 143.9%
Oruka Therapeutics, Inc. (NASDAQ:ORKA) is one of the best performing healthcare stocks so far in 2026. Leerink lifted the price target on Oruka Therapeutics, Inc. (NASDAQ:ORKA) to $120 from $109 on April 30, reaffirming an Outperform rating on the shares. In a separate development, Oruka Therapeutics, Inc. (NASDAQ:ORKA) announced on April 27 positive interim results from its EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis. ORKA-001 is a novel half-life extended IL-23p19 monoclonal antibody.
The company reported that ORKA-001 attained 63.5% (40/63) PASI 100 at Week 16, with a favorable safety profile consistent with the IL-23p19 class. It also stated that the updated Phase 1 PK/PD data continues to support the potential for once-yearly dosing, with longer-term EVERLAST-A data anticipated in H2 2026.
Dr. Bruce Strober, MD, PhD, Clinical Professor of Dermatology at Yale University School of Medicine and lead investigator for EVERLAST-A, stated that the data with ORKA-001 are “highly compelling”, adding that if “this type of efficacy and safety profile could be available with dosing once to twice per year, it would represent a major step forward for the field”.
Oruka Therapeutics, Inc. (NASDAQ:ORKA) is a biotechnology company that focuses on the development of novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002.
4. Enliven Therapeutics, Inc. (NASDAQ:ELVN)
YTD Share Price Gain: 167.5%
Enliven Therapeutics, Inc. (NASDAQ:ELVN) is one of the best performing healthcare stocks so far in 2026. On April 30, Mizuho reaffirmed an Outperform rating on Enliven Therapeutics, Inc. (NASDAQ:ELVN), setting a price target of $45. The rating update came after Merck noted during its fiscal Q1 earnings call that it believes Terns’ TERN-701 major molecular response “will be north of 50% and within the confidence interval as had been publicly stated.” The firm believes the comments to be a positive for ELVN-001, adding that today’s “high-level quantification” only further supports the significant degradation.
Enliven Therapeutics, Inc. (NASDAQ:ELVN) also received a rating update from Clear Street on April 27. The firm lifted the price target on the stock to $55 from $36, maintaining a Buy rating on the shares. The firm stated that it left meetings with management with increased conviction in ELVN-001 as a differentiated ATP-site binder for BCR-ABL1. For additional reference, Enliven Therapeutics, Inc. (NASDAQ:ELVN) reported in fiscal Q4 and full year 2025 earnings that it has a strong balance with $463 million in cash, cash equivalents, and marketable securities, which is anticipated to provide cash runway into the first half of 2029.
Enliven Therapeutics, Inc. (NASDAQ:ELVN) is a clinical-stage biopharmaceutical company with a focus on the discovery and development of small-molecule therapeutics. The company’s pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002.
3. Tango Therapeutics, Inc. (NASDAQ:TNGX)
YTD Share Price Gain: 171.01%
Tango Therapeutics, Inc. (NASDAQ:TNGX) is one of the best performing healthcare stocks so far in 2026. Stifel lifted the price target on Tango Therapeutics, Inc. (NASDAQ:TNGX) to $40 from $24 on April 27, maintaining a Buy rating on the shares. The firm cited elevated conviction for the PRMT5 inhibitor + RAS(ON) inhibitor synergy in pancreatic ductal adenocarcinoma.
For additional context, Tango Therapeutics, Inc. (NASDAQ:TNGX) reported in its fiscal Q4 and full year 2025 results that it held $343.1 million in cash, cash equivalents, and marketable securities, which it expects to fund operations into 2028. It further reported that collaboration revenue for the quarter was $0 compared to $5.4 million for the same period in 2024, and $62.4 million for the full year, compared to $30.0 million for the prior year period.
It added that all of the remaining deferred revenue under the Gilead collaboration was recognized as collaboration revenue during fiscal Q3 2025 as a result of the truncation of the collaboration agreement, which concluded all research activities.
Tango Therapeutics, Inc. (NASDAQ:TNGX) is a clinical-stage biotechnology company that discovers and delivers precision cancer medicines. The company is also involved in the identification of novel targets and the development of new drugs directed at tumor suppressor gene loss in defined patient populations with high unmet medical need.
2. Erasca, Inc. (NASDAQ:ERAS)
YTD Share Price Gain: 178.2%
Erasca, Inc. (NASDAQ:ERAS) is one of the best performing healthcare stocks so far in 2026. The Fly reported on May 4 that JPMorgan is maintaining an Overweight rating on Erasca, Inc. (NASDAQ:ERAS) and recommends buying the stock at current levels. The firm believes that the stock boasts several catalysts over the coming months and believes that the recent weakness in its shares is overdone. JPMorgan further told investors in a research note that ERAS-0015 has potential for safety differentiation and looks efficacious in non-small cell lung cancer.
Erasca, Inc. (NASDAQ:ERAS) also received a rating update from H.C. Wainwright on April 28. The firm maintained a Buy rating on the stock with a $20 price target, with the rating coming after the company reported preliminary Phase 1 data for ERAS-0015. H.C. Wainwright told investors in a research note that while the data shows a “clear step-up in early efficacy” relative to the pre-readout bar, especially in lung cancer, it is significant to note that ERAS-0015’s safety profile is “directionally favorable but not without caveats.” It added that the dataset is “not fully clean”, and this “introduces tension with the otherwise benign safety narrative and raises questions around attribution and reporting consistency”.
Erasca, Inc. (NASDAQ:ERAS) is a clinical-stage precision oncology company with a focus on the discovery, development, and commercialization of therapies for patients with RAS/MAPK pathway-driven cancers. The company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline that comprises modality-agnostic programs.
1. Veradermics, Incorporated (NYSE:MANE)
YTD Share Price Gain: 204.1%
Veradermics, Incorporated (NYSE:MANE) is one of the best performing healthcare stocks so far in 2026. On April 27, Citi lifted the price target on Veradermics, Incorporated (NYSE:MANE) to $120 from $85, reaffirming a Buy rating on the shares. The rating update came after the company announced positive topline results from Part A of its Phase 2/3 trial evaluating VDPHL01 in male pattern hair loss. The firm stated that the data “exceeded our base-case bar across all endpoints”, adding that the safety profile was clean. Citi lifted its view of the odds of success to 75%, and now models 2035 risk-adjusted peak sales of $3 billion, up from the previous $2 billion.
Veradermics, Incorporated (NYSE:MANE) announced on April 27 positive topline results from Part A of its randomized, double-blind, placebo-controlled Phase 2/3 clinical trial evaluating VDPHL01 in over 500 males with mild-to-moderate pattern hair loss. VDPHL01 is a proprietary extended-release oral minoxidil formulation, and Veradermics, Incorporated (NYSE:MANE) believes that the result positions the formulation to potentially become the first FDA-approved oral pill for pattern hair loss in nearly 30 years, as well as a potential best-in-indication treatment option for the 50 million men with pattern hair loss in the United States.
Veradermics, Incorporated (NYSE:MANE) is a late clinical-stage biopharmaceutical company with a focus on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent dermatological and aesthetic conditions.
While we acknowledge the potential of MANE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MANE and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
